We are improving the lives of people suffering from mental illness and substance use disorders


What we do

US Pharma

US Pharma

HQ & Pipeline

HQ & Pipeline

Digital Therapeutics

Digital Therapeutics

 Discover our story 

Key News

MARCH 15, 2023
New date for publication of the Annual Report 2022 is March 28

FEBRUARY 3, 2023
NDA submitted with the FDA for OX124 a highdose medication for opioid overdose

Listed on Nasdaq Stockholm´s mainlist

Orexo is listed on Nasdaq Stockholm´s main list and can also be traded in the US at the OTCQX Market.

MODIA® - our digital therapy for opioid use disorder

  • to be used along with pharmaceuticals
  • 180 days treatment
  • grounded in cognitive behavioral therapy techniques
  • available 24/7
  • ongoing clinical trial incl. more than 430 patients

Orexo Social

16 March 2023

March 28 is the new date for publication of our Annual Report for 2022, also incl our Sustainability Report. Earli… https://t.co/4Q5X1Vr0jr

13 March 2023

Brief interview with CEO Nikolaj Sørensen, conducted at the Stockholm Corporate Finance Life Science Seminar last w… https://t.co/glFZPUDR1r

13 March 2023

Last week our CEO presented at Stockholm Corporate Finance Life Science Day. View the full presentation below incl.… https://t.co/jiQM78hmEU

Financial Snapshot

Group net revenues

624  MSEK



-115 MSEK


US Pharma segment EBIT

308 MSEK


Cash position

352 MSEK

Q4 2022

1 Last Twelve Months, Q122-Q422, for more information about financial development Link